Clinical Trial Update: A Phase II Clinical Study to Evaluate HLX43 in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase II clinical trial evaluating HLX43 for recurrent or metastatic head and neck squamous cell carcinoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• HLX43

Snippet

Sponsor: Shanghai Henlius Biotech | Conditions: Carcinoma of Head and/or Neck | Phase 2 | Status: RECRUITING